Skip to main content
Clinical Trials/NCT02691663
NCT02691663CompletedNot Applicable

Dietary Acid Load, Kidney Function and Disability in Elderly

Wake Forest University Health Sciences1 site in 1 country196 target enrollmentStarted: February 1, 2016Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
196
Locations
1
Primary Endpoint
Blood Bicarbonate

Study Overview

Brief Summary

The purpose of this research study is to determine the effect of a bicarbonate supplement on kidney function and physical function.

Detailed Description

Physical decline and frailty result from age- and disease-related impairments in organs and tissues. Frailty research has focused on the musculoskeletal, neurological and circulatory systems; yet interventions targeting these systems had limited success in preventing and treating functional decline. Given the aging of the US population, additional avenues for intervention development are urgently needed. Fragility and disability in people ≥65 strongly correlate with declining kidney function and are evident even in early stages of chronic kidney disease (CKD). Moreover, CKD is highly prevalent in the elderly and associates with sarcopenia, osteopenia, and increased incidence of fractures/falls with hospitalization. Low serum bicarbonate and impaired acid-base homeostasis, also common in CKD, are increasingly appreciated as contributors to functional decline with advancing age. With aging, the adaptive response of the kidney to low serum bicarbonate and high metabolic acid load becomes maladaptive, facilitating CKD progression. Conversely, in adult patients with CKD, maintenance of serum bicarbonate at 24 meq/L with oral bicarbonate supplementation or increased consumption of base-forming foods slows CKD progression.

The study investigators propose the current study and protocol based on the evidence summarized above and our preliminary studies, which suggest that: In the Health Aging and Body Composition cohort (age 70-79) lower dietary acid load associates with stable kidney function over a 7-year follow-up, independent of age, race, gender, BMI, diabetes, hypertension or smoking status; metabolomics analysis in participants of the African American Diabetes Heart Study suggested that it is feasible to segregate a urine metabolomics profile in the early stages of CKD (stages 2 and 3), and that lower consumption of base-forming fruits and vegetables and higher rates of acid excretion may be associated with CKD and its progression.

The investigators therefore hypothesized that decreasing metabolic acid production by titrating dietary acid load may ameliorate the generally expected, age-related decline in kidney function, decrease loss of lean body mass, preserve physical function, and ameliorate disability. This is not a treatment study as the investigators are exploring the effects of bicarbonate on these age-related issues.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Prevention
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
65 Years to — (Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Age 65 +years of age
  • •Short physical performance battery (SPPB) score>3
  • •Estimated glomerular filtration rate (eGFR) 30-89
  • •Net endogenous acid production (NEAP) >=40 mEq/d
  • •Willing to provide informed consent and agrees to randomization
  • •Not involved in another intervention study

Exclusion Criteria

  • •Uncontrolled (>160 mg/dl fasting blood glucose), insulin-dependent diabetes and/or uncontrolled hypertension (Systolic Blood Pressure >160, Diastolic BP>100)
  • •a current diagnosis of psychotic disorder
  • •take more than 14 alcoholic drinks per week
  • •plan to relocate out of the study area within the next year
  • •self-reported inability to walk across a room
  • •those who reside in nursing homes
  • •have difficulty communicating with study personnel due to speech or language or hearing problems
  • •had cancer requiring treatment in the past 1 year
  • •lung disease requiring regular use of corticosteroids or of supplemental oxygen
  • •cardiovascular disease (Class III or IV congestive heart failure)
  • •significant valvular disease, uncontrolled angina
  • •myocardial infarction, major heart surgery (i.e., valve replacement or bypass surgery) in past 6 months
  • •stroke, deep vein thrombosis, or pulmonary embolus in the past 6 months, Parkinson's disease or other progressive neurological disorder
  • •other medical or behavioral factors that in the judgment of the principal investigator may interfere with study participation or the ability to follow the intervention
  • •clinical judgment concerning safety or noncompliance
  • •Individuals with BMI <18.5; or weight loss >4% in last 6 months
  • •Montreal Cognitive Assessment (MoCA) score under 24
  • •End Stage Renal Disease (ESRD) on dialysis or primary kidney disease
  • •Other illness of such severity that life expectancy is less than 12 months
  • •Smoking; defined as not smoking for more than a year prior to the study
  • •Serum Bicarbonate (HCO3)>30 milliequivalents per liter (mEq/L); serum potassium out of normal range

Arms & Interventions

Oral bicarbonate supplementation group

Active Comparator

0.3 meq/kg/day NaHCO3 capsules

Intervention: Oral bicarbonate supplementation (Dietary Supplement)

Placebo group

Placebo Comparator

Methylcellulose capsules

Intervention: Placebo (Dietary Supplement)

Outcomes

Primary Outcomes

Blood Bicarbonate

Time Frame: six months post baseline

measurement taken from a blood sample; measures how much carbon dioxide is in your blood; a normal result is between 23 and 29 millimoles per liter (mmol/L) for adults

Blood Bicarbonate

Time Frame: baseline

measurement taken from a blood sample; measures how much carbon dioxide is in your blood; a normal result is between 23 and 29 millimoles per liter (mmol/L) for adults

Secondary Outcomes

  • Average Body Mass Index (BMI)(six months post baseline)
  • Estimated Glomerular Filtration Rate (eGFR)(six months post baseline)
  • Measurement of Kidney Function (eGFR) at Baseline.(baseline)
  • Estimated Glomerular Filtration Rate (eGFR) - Measurement of Kidney Function After 6 Months Post Baseline(six months post baseline)
  • Urinary Albumin to Creatinine Ratio (ACR)(six months post baseline)
  • Percentage of Screened Participants Randomized(baseline)
  • Carbon Dioxide Blood Test(six months post baseline)
  • 400 Meter Walk Time(six months post baseline)
  • Femoral Neck Bone Mineral Density(six months post baseline)
  • Percent Adherence: Percentage of Pills Taken(6 months post baseline)
  • Hip Bone Mineral Density(six months post baseline)
  • 400 Meter Walk Time(three months post baseline)
  • Carbon Dioxide Blood Test(baseline)
  • 400 Meter Walk Time(baseline)
  • Estimated Glomerular Filtration Rate (eGFR)(baseline)
  • Estimated Glomerular Filtration Rate (eGFR)(three months post baseline)
  • Hip Bone Mineral Density(baseline)
  • Femoral Neck Bone Mineral Density(baseline)
  • Average Body Mass Index (BMI)(baseline)
  • Average Body Mass Index (BMI)(three months post baseline)
  • Urinary Albumin to Creatinine Ratio (ACR)(baseline)
  • Urinary Albumin to Creatinine Ratio (ACR)(three months post baseline)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials